<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR20">
 <label>20.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Schadendorf</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Wolchok</surname>
    <given-names>JD</given-names>
   </name>
   <name>
    <surname>Hodi</surname>
    <given-names>FS</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials</article-title>
  <source>J Clin Oncol</source>
  <year>2017</year>
  <volume>35</volume>
  <issue>34</issue>
  <fpage>3807</fpage>
  <lpage>3814</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2017.73.2289</pub-id>
  <?supplied-pmid 28841387?>
  <pub-id pub-id-type="pmid">28841387</pub-id>
 </element-citation>
</ref>
